Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
Standard
Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. / Jacobsen, Frank; Kraft, Juliane; Schroeder, Cornelia; Hube-Magg, Claudia; Kluth, Martina; Lang, Dagmar S; Simon, Ronald; Sauter, Guido; Izbicki, Jakob R; Clauditz, Till S; Luebke, Andreas M; Hinsch, Andrea; Wilczak, Waldemar; Wittmer, Corinna; Büscheck, Franziska; Höflmayer, Doris; Minner, Sarah; Tsourlakis, Maria Christina; Huland, Hartwig; Graefen, Markus; Budäus, Lars; Thederan, Imke; Salomon, Georg; Schlomm, Thorsten; Melling, Nathaniel.
in: NEOPLASIA, Jahrgang 19, Nr. 9, 09.2017, S. 707-715.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
AU - Jacobsen, Frank
AU - Kraft, Juliane
AU - Schroeder, Cornelia
AU - Hube-Magg, Claudia
AU - Kluth, Martina
AU - Lang, Dagmar S
AU - Simon, Ronald
AU - Sauter, Guido
AU - Izbicki, Jakob R
AU - Clauditz, Till S
AU - Luebke, Andreas M
AU - Hinsch, Andrea
AU - Wilczak, Waldemar
AU - Wittmer, Corinna
AU - Büscheck, Franziska
AU - Höflmayer, Doris
AU - Minner, Sarah
AU - Tsourlakis, Maria Christina
AU - Huland, Hartwig
AU - Graefen, Markus
AU - Budäus, Lars
AU - Thederan, Imke
AU - Salomon, Georg
AU - Schlomm, Thorsten
AU - Melling, Nathaniel
N1 - Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2017/9
Y1 - 2017/9
N2 - Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P<.0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P<.0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P<.0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers.
AB - Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P<.0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P<.0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P<.0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers.
KW - Journal Article
U2 - 10.1016/j.neo.2017.06.003
DO - 10.1016/j.neo.2017.06.003
M3 - SCORING: Journal article
C2 - 28830008
VL - 19
SP - 707
EP - 715
JO - NEOPLASIA
JF - NEOPLASIA
SN - 1476-5586
IS - 9
ER -